TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02150733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 360 mg twice daily in the extension phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg twice daily in the extension phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once daily in the extension phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once every other day in the extension phase
Study: NCT00254176

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral cysteine-HCl supplementation
Description: cysteine-HCl supplementation 121 mg per kg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - added premasol
Description: Premasol 121 mg per kg per day
Study: NCT03053063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match SEL 6 mg
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SEL 6 mg
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match SEL 18 mg
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SEL 18 mg
Description: Tablets administered orally once daily
Study: NCT04271319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BEST™ HVPC microcurrent electrical stimulation PRO-SPORT Ultra® Device
Description: Participants will receive treatment with an active electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PRO-SPORT Ultra® Device
Description: Participants will receive treatment with a sham electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Sham PRO-SPORT Ultra® device will be used. The built in electrodes and the accessory port for connecting the lead wire to the electrode pads will be disconnected internal to the device. The device will power on with the same sounds and indications.
Study: NCT03030989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate 2% Wipe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Wipe
Study: NCT00569647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Hypnosis
Description: Use of virtual reality headset to induce hypnotic state

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no use of device
Study: NCT02130804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate (4 g/day)
Description: Given orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (4 g/day)
Description: Given orally twice daily
Study: NCT04830384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully Active
Description: 7 subjects will be dispensed active treatment devices with light and music fully functional

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LLLT Only
Description: 7 subjects will be dispensed active treatment devices with only light functional

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Music Only
Description: 7 subjects will be dispensed placebo comparator devices with only music functional

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: 7 subjects will be dispensed placebo or sham devices with no light or music functional
Study: NCT03706885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sustiva Pill
Description: One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustiva Pill
Description: One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustiva Pill
Description: One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
Study: NCT01051544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FVIII Concentrates
Description: Patients will be centrally randomized to receive a von Willebrand factor-free FVIII concentrate (recombinant or plasma-derived, monoclonally-purified). The choice of product brand will be based on physician / patients preferences.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FVIII/VWF concentrates
Description: Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.
Study: NCT02490787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concizumab
Description: Administered subcutaneously (s.c., under the skin) at five different dose levels (ranging from 0.25 to 1.5 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin)
Study: NCT02004886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893
Description: 10 mg and 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893
Description: 10 mg and 100 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg metformin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching MK-0893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching MK-0893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching MK-0893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching MK-0893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching metformin
Study: NCT01899742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol 62.5/25 mcg
Description: Inhalation Powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 mcg
Description: Inhalation Powder
Study: NCT03705650

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Limited Echocardiogram
Description: STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance, feedback and interpretation assistance to users during image acquisition. For this study, CMAs will use EchoGPS to perform point-of-care echocardiogram examinations.
Study: NCT01690728

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: The intervention program will continue for six month consisting of two weekly sessions of 40 min exercise supervised by physiotherapists. The supervised exercise program will take place at the training center Fitness.dk in Esbjerg and Kolding. It will be in cooperation with physiotherapists at the Therapy Department of Sydvestjysk Sygehus Esbjerg and the Therapy Department of Fredericia and Kolding Sygehus, Sygehus Lillebælt. The exercise program at the two centers will be equal. In addition the patients will be provided with free access to a fitness center. The patient will be encouraged to do at least 3.5 hours of moderate to vigorous physical activity per week.
Study: NCT02354755

Intervention type: DEVICE
Intervention: Psychomotor vigilance test (PVT
Description: The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).

Intervention type: DEVICE
Intervention: Psychomotor vigilance test (PVT
Description: The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).
Study: NCT03321513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreous aflibercept
Description: Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.~Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.~Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using sterile technique

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreous aflibercept
Description: Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.~Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.~Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using sterile technique

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Deferred Aflibercept Group
Description: Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.~Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.~Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using a sterile technique.
Study: NCT05126979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Split Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Split Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02807740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Each session will consist of multiple exercises. These ones are already described, each exercise will be performed by the patient for 4 minutes followed by a 1 minute of rest.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional rehabilitation program
Description: In each C rehabilitation session, patients underwent 3 phases: 1) Warm-up phase: passive mobilization of main joints and muscular strengthen of lower limbs; 2) Active phase (both standing than seated): exercises of motor coordination with upper and lower limbs, balance training, start and stop exercises, deambulation training; 3) cool-down phase (with seated patient): manipulation exercises, mobilization exercises, respiratory exercises.
Study: NCT02593305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super Beets
Description: Nitrate rich beetroot powder (10g/day) for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super Beets
Description: Nitrate rich beetroot powder (10g/day) for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super Beets Placebo
Description: Nitrate deficient beetroot powder (10g/day) for 4 weeks
Study: NCT02354755

Intervention type: DEVICE
Intervention: Psychomotor vigilance test (PVT
Description: The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).
Study: NCT02496351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS INTERVENTION
Description: 24 hours of TENS treatment in the immediately postoperative of limb amputation
Study: NCT02344251

Intervention type: DEVICE
Group type: OTHER
Intervention: MEMS Cap
Description: MEMS Track Cap records when the medication bottle is opened and closed

Intervention type: DEVICE
Group type: OTHER
Intervention: ID-Cap
Description: ID-Cap Tag is an ingestible medical device for detecting the presence of an ingested capsule inside the gastrointestinal (GI) tract.
Study: NCT00041106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01040195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate, Hydroxychloroquine
Description: Methotrexate will be prepared as unmarked tablets of 2.5 mg strength each and Hydroxychloroquine as unmarked tablet of 200 mg strength. Patients will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebos (for methotrexate and hydroxychloroquine)will be prepared and prescribed in identical fashion as the methotrexate and hydroxychloroquine in the combination DMARD arm.
Study: NCT01689246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237 150 mg/day
Description: TRx0237 75 mg tablets will be administered twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237 250 mg/day
Description: TRx0237 125 mg tablets will be administered twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
Study: NCT01833624

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peptamen® AF
Description: Comparison of two types of enteral nutrition feeding: Peptamen® AF and Sondalis® HP

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sondalis® HP
Study: NCT02657213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimed 640G with smartguard activated
Description: Patients will be equipped with a Minimed 640G insulin pump coupled with Enlite sensor with SmartGuard activation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Minimed 640G with smartguard off
Description: Patients will be equipped with Minimed 640G insulin pump coupled with Enlite glucose sensor without SmartGuard activation
Study: NCT03823079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO 300u/kg, subcutaneous injection, qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltitrexed
Description: 3mg/m2 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: 3mg/m2 q3w

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhIL-11
Description: rhIL-11 50ug/kg, subcutaneous injection, qd
Study: NCT04042766

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser vaginal treatment
Description: Er:YAG laser

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: laser vaginal treatment
Description: Er:YAG laser
Study: NCT01460654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone Gel (Fortesta) 40mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone
Description: Testosterone Gel (Fortesta) 40mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate
Description: Alendronate (Fosamax) 70mg every week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Alendronate (Fosamax) 70mg every week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Alendronate
Description: A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Testosterone
Description: Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.
Study: NCT02899559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message
Description: Participants will receive one of three messages at the end of a survey, two of which are experimental messages and one of which is a control message.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message
Description: Participants will receive one of three messages at the end of a survey, two of which are experimental messages and one of which is a control message.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message
Description: Participants will receive one of three messages at the end of a survey, two of which are experimental messages and one of which is a control message.
Study: NCT04726644

Intervention type: PROCEDURE
Intervention: hernia repair
Description: different methods for hernia repair
Study: NCT01512069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Health Planner on diet and exercise
Description: URL is closed~The program is 12-week program, provides tailored information on the exercise and diet based on the stage of motivational readiness of TTM. The program is designed to allow to plan a regular exercise of 12.5 MET per week and to recommend to eat number of portions from six food groups for balanced diet tailored to individual's BMI, ideal body weight, and calories needed per day. The program provide the feedback based on the achievement of goals of the behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-tailored booklet on exercise and diet
Description: The active control group is provided non-tailored booklet on exercise and diet, whose information is same as web-based program except stage-matching.
Study: NCT00885742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FXIII Concentrate (Human)
Description: Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who did not complete the pharmacokinetic study (Factor XIII Study BI71023_2002 \[NCT00883090\]) will initially receive FXIII Concentrate (Human) at a dose of 40 U/kg by intravenous (IV) infusion.
Study: NCT02589236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavosonstat
Description: GSNOR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavosonstat
Description: GSNOR inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control sample with only capsule excipients and fillers
Study: NCT02935504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRogram In Support of Moms (PRISM)
Description: PRISM Intervention Provider and staff training Webinar Delivered in person Engage providers - Registered Nurses (RN) and Patient Care Assistants (PCA) and ensure they attend:~Toolkit Care coordination Psychiatric consultation Implementation support~1. Engage clinic leaders and staff~2. Identify leadership group and prepare for change~3. Assess readiness to implement PRISM~4. Identify steps to achieve goals~5. Implement PRISM components into the clinic~6. Support, encourage and sustain change Office prompts Screening procedures Plus all MCPAP for Moms intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MCPAP for Moms
Description: MCPAP for Moms Provider and staff training Delivered via web RN and PCA admin staff recommended to attend 30-60 minute presentation on perinatal depression Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns Access to one-time face-face evaluation with patient by a MCPAP for Moms psychiatrist for assessment and treatment recommendations for Ob/Gyn provider Access to Provider Toolkit which includes assessment and treatment protocols (available at www.mcpapformoms.org) Resource provision/referrals